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Abstract
Background: The clinical relevance of human papillomavirus type 16 (HPV16) DNA methylation has not been well
documented, although its role in modulation of viral transcription is recognized.
Methods: Study subjects were 211 women attending Planned Parenthood clinics in Western Washington for routine
Papanicolaou screening who were HPV16 positive at the screening and/or subsequent colposcopy visit. Methylation of 11
CpG dinucleotides in the 39 end of the long control region of the HPV16 genome was examined by sequencing the cloned
polymerase chain reaction products. The association between risk of CIN2/3 and degree of CpG methylation was estimated
using a logistic regression model.
Results: CIN2/3 was histologically confirmed in 94 (44.5%) of 211 HPV16 positive women. The likelihood of being diagnosed
as CIN2/3 increased significantly with decreasing numbers of methylated CpGs (meCpGs) in the 39 end of the long control
region (Pfor trend=0.003). After adjusting for HPV16 variants, number of HPV16-positive visits, current smoking status and
lifetime number of male sex partners, the odds ratio for the association of CIN2/3 with $4 meCpGs was 0.31 (95%
confidence interval, 0.12–0.79). The proportion of $4 meCpGs decreased appreciably as the severity of the cervical lesion
increased (Pfor trend=0.001). The inverse association remained similar when CIN3 was used as the clinical endpoint. Although
not statistically significant, the $4 meCpGs-related risk reduction was more substantial among current, as compared to
noncurrent, smokers.
Conclusion: Results suggest that degree of the viral genome methylation is related to the outcome of an HPV16 cervical
infection.
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Introduction
Human papillomavirus type 16 (HPV16) is the most carcino-
genic type of HPV [1,2]. It is also the type commonly present in
healthy women [3,4,5]. Most infections are transient with only a
small fraction leading to the development of cervical cancer and its
precursor lesion, cervical intraepithelial neoplasia grades 2 or 3
(CIN2/3). Given a recent recommendation of adding a test for
oncogenic HPV types to programs for cervical cancer control
[6,7], it is worthwhile to understand factors which might dis-
criminate between infections that are neoplastic and those that are
self-limited. Studies in vitro have shown that methylation of the
HPV16 genome results in a substantial repression of viral tran-
scription and DNA replication [8,9,10,11]. Because the expression
of HPV16 oncogenes is essential to initiate transformation of
infected epithelial cells, viral DNA methylation is likely to be
involved in the outcome of infection.
DNA methylation refers to the addition of a methyl group by
DNA methyltransferases to position 5 of the ring of cytosine (C),
which occurs predominantly in the position immediately preced-
ing a guanosine (G) in the DNA sequence. This change forms
methylated CpG dinucleotides (meCpG), which is a major epi-
genetic mechanism for controlling gene expression in mammalian
cells [12,13,14]. Unlike the wealth of evidence concerning the
impact of aberrant promoter methylation of various cellular genes
on the development of cervical cancer and its precancerous lesions
[15,16], reports of the potential clinical relevance of HPV16 DNA
methylation are rare. Findings from a few small studies are
inconsistent, with lower levels of CpG methylation among women
with, compared to those without, cervical precursor lesions found in
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undetermined whetherothermethylation-related exposures,suchas
age and smoking [23,24,25,26,27], play a role in potential risks
posed by HPV16 DNA methylation.
In this study, we describe the patterns of meCpGs in the 39 end
of the long control region of the HPV16 genome among women
with and without a histological diagnosis of CIN2/3.
Materials and Methods
Study subject and design
Study subjects were a subset of women who participated in a
study of new screening strategies for cervical cancer prevention. A
detailed description of the original study design and population is
presented elsewhere [28]. Briefly, the original study population
was composed of women seen at 1 of 3 Planned Parenthood clinics
in Western Washington for routine Papanicolaou (Pap) screening.
Women were eligible if they were between 18 and 50 years of age,
sexually active, not pregnant or immunocompromised, and had no
history of hysterectomy or treatment for CIN. Between January
1997 and August 2002, a total of 5,103 women were enrolled. All
participants underwent the standardized screening procedure,
including a questionnaire, gynecologic examination, and collection
of cervical samples for thin-layer cytology and HPV DNA testing.
HPV DNA was detected by polymerase chain reaction (PCR)-
based reverse-line blot. Women were referred for colposcopy and
biopsy if they had a cytologic diagnosis of atypical squamous cells
of undermined significance (ASC-US) or greater, or a positive test
for an oncogenic HPV type(s). In addition, a random sample
(10%) of women with normal screening results was also invited to
undergo colposcopy and biopsy. At the colposcopy visit, cervical
samples were collected again for thin-layer cytology and HPV
DNA testing. Colposcopically-guided biopsies of the visible lesions
were obtained, or if there was no visible lesion, a biopsy was taken
at the 12-o’clock position on the cervix. Endocervical curettage
was performed if the colposcopy was unsatisfactory, the screening
cytology was high-grade squamous intraepithelial lesion (HSIL)
but no lesion was visible during the colposcopy examination, or
the lesions extended into the endocervical canal. A treatment with
loop electrosurgical excision procedure was offered to women with
histologically-confirmed CIN2/3.
A study participant was eligible for the present study, if she
underwent colposcopy and biopsy and had HPV16 DNA detected
at the screening and/or colposcopy visit. In total, 327 (6.4%) of
5,103 initially screened women were positive for HPV16. Of them,
104 were excluded including 78 who did not return for colposcopy,
one with an unsatisfactory histologic diagnosis, and 25 with infsuf-
ficient samples for methylation testing. We additionally excluded 12
women because of failure to PCR-generate target fragments from
their samples for methylation analyses. This left 211 women in the
analysis, including 33 positive for HPV16 at the screening visit
alone, 34 at the colposcopy visit alone, and 144 at both. HPV16
DNA methylation was assayed in cervical samples collected at the
colposcopy visit for all except for those who had HPV16 detected at
the screening visit alone. The present study utilized existing data
and cervical samples collected in the screening study. A written
informed consent regarding use of samples for future research
was obtained from all participants. The institutional review board
at the University of Washington approved the protocols for this
study.
Laboratory methods
DNA was extracted and purified from an aliquot of 200 mlo f
cervical swab sample in Specimen Transport Medium with
QIAamp DNA Mini kit (Qiagen, Valentia, CA) and suspended in
100 ml AE buffer (10 mM Tris?Cl, 0.5 mM EDTA, pH 9.0).
Bisulfite treatment of 50 to 150 ng sample DNA, which converts
all unmethylated cytosines to uracils but leaves methylated cytosines
intact, was completed using EpiTectH Bisulfite kit (Qiagen)
according to the manufacturer’s instructions. SiHa cellular DNAs
with and without a treatment by CpG methyltransferase SssI (New
England Biolabs, Ipswich, MA) were included in each run of the
assay as the methylated and unmethylated controls, respectively, to
monitor the completeness of bisulfite conversion.
The modified DNAs were PCR-amplified with a pair of primers
(forward, 59-tagttttatgttagtaattatggtt; reverse, 59-tattaaaagagaattg-
taatgttttaggat) for the 39 end of the long control region of the
HPV16 genome during which uracils were converted to thymines.
We chose this region as a target because it is the main part of the
viral regulatory region, which controls transcription of the E6 and
E7 oncogenes. The reaction was setup in a total volume of 25 ml
containing 1 ml sample DNA, 0.2 mM dNTPs, 0.5 mM primers,
2.5 mM MgCl2, 16buffer II, and 1.25 unit AmpliTaq Gold DNA
polymerase (Applied Biosystems, Foster City, CA). PCR amplifi-
cation was carried out with the following profile: 94uC for
9 minutes to activate the polymerase; 44 cycles at 94uC for
30 seconds, 55uC for 30 seconds, and 68uC for 45 seconds; and a
7-minute terminal extension at 68uC.
The PCR-generated DNA fragments were cloned into plasmids
using a TOPO TA Cloning kit according to the protocol
recommended by the manufacturer (Invitrogen, Carlsbad, CA).
Clones were screened by colony PCR followed by electrophoreses
on the agarose gel to examine presence of target inserts. Plasmid
DNAs from each clone were purified with a QIAprep Spin
Miniprep Kit (Qiagen). The purified DNA templates were
sequenced using a BigDye
TM Sequencing kit (Applied Biosystems).
DNA sequences were analyzed using the Sequencer
TM package
(Gene Codes Corp., Ann Arbor, MI), which shows cytosine if the
original cytosine is methylated or thymine if the original cytosine is
unmethylated. We selected 3 clones per sample for sequencing. A
CpG site was considered methylated, if $1 clone displayed a
methylated cytosine at this site.
Statistical analysis
The main goal of the analyses is to examine the effects of
HPV16 DNA methylation on the development of histologically
confirmed cervical lesion. The 39 end of the long control region
covers 11 CpG sites: 5 (positions 7535, 7554, 7677, 7683, and
7695) within the enhancer region, 1 (position 7862) within the viral
replication origin, and 5 (positions 31, 37, 43, 52, and 58) within
the promoter region [18]. The number of meCpGs was
categorized as 0, 1, 2–3 and $4 to reflect the extensiveness of
methylation in the long control region and 0, 1, $2 to reflect the
extensiveness of methylation in the enhancer or promoter region.
One sample displayed a C-to-G alteration at position 43 in 2
clones and a methylated cytosine in the third. A meCpG at
position 43 was assigned to this sample. Our HPV16 variant data
suggest that most African variants have a C-to-T alteration at
position 31. When this CpG site was excluded from the analysis for
samples positive for the African variants (n=13), the results
remained similar (data not shown).
CIN2/3, otherwise specified, was the primary endpoint in all
analyses. For women with more than 1 histologic diagnosis (due to
either repeated biopsies or tissues from different sampling proce-
dures), the most severe one was used as the final diagnosis. Two
women had a diagnosis of CIN3 on their endocervical curettage
sample and microinvasive or invasive squamous cell carcinoma on
their loop electrosurgical excision sample. The methylation patterns
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not shown). Thus, they were grouped with CIN3 cases for analyses.
A logistic regression model [29] was used to estimate odds ratios
(ORs)and95%confidenceintervals(CIs)fortheassociationbetween
risk of CIN2/3 and degree of CpG methylation in various regions.
The ORs were adjusted for HPV16 variants, number of HPV16
positive visits, current smoking status, and lifetime number of male
sex partners. In this study, the methylation status was defined based
on 3 clones per sample. To determine whether sequencing more
clones per sample would alter estimates of risk association, we
computed 95% CIs using a parametric bootstrap method with
10,000 repetitions of re-sampling 5 or 10 clones per specimen. Odds
ratios were calculated 10,000 times; the lower and higher bounds of
the 95% CI were given by the 250th and 9750th bootstrap odds
ratios, respectively. In addition, we examined a potential of
interaction between smoking and methylation using the likelihood
ratio test comparing models with and without the interaction term.
A Cochran-Armitage test was used to assess the trend of
decrease in proportions of CIN2/3 with increasing numbers of
meCpGs in the 39 end of the long control region and the trend of
decrease in proportions of $4 meCpGs in this region with
increasing severities of cervical lesion. We also assessed distribu-
tions of characteristics of women with versus without CIN2/3 by
x
2 tests, including age at screening, race, lifetime number of male
sex partners, having new male sex partners since screening, age at
the first sexual intercourse, smoking status, current use of
hormonal contraceptives, HPV16 variants, HPV16 positive visits,
co-infection with other oncogenic types (i.e., HPV18/31/33/35/
39/45/51/52/56/58/59/68), and cervical cytology. Characteris-
tics were based on information at screening with the exception of
new male sex partners and co-infection with other oncogenic
types, which were based on information at the colposcopy visit and
at the visit from which the sample was tested for methylation,
respectively. A Student t-test was used to compare the mean
lengths of intervals from the screening to colposcopy visit between
women with and without CIN2/3. All statistical tests were
conducted at the 5% two-sided significance level.
Results
CIN2/3 was histologically confirmed in 94 (44.5%) of 211
HPV16-positive women. The mean length of intervals between the
screening and colposcopy visits was 2.44 (SD, 3.24) months for
women with CIN2/3 and 3.08 (SD, 3.94) months for those
without (p=0.20). As shown in Table 1, women with, compared to
without, CIN2/3 were more likely to be positive for HPV16 non-
European variants (P=0.03), self-report as current smokers
(P=0.05), and have abnormal cytologic findings at screening
(P,0.001) and a detectable HPV16 infection at both screening
and colposcopy visits (P=0.01).
Patterns and frequencies of HPV16 DNA methylation
Figure 1 summarizes the patterns of methylation in the 39end of the
long control region. An assessment of a total of 2,321 CpGs (11 CpGs
per sample for a total of 211 samples) revealed 357 (15.4%) meCpGs
that were distributed in scattered patterns. The overall frequency of
meCpGs in the region examined was significantly lower among
women with, compared to without, CIN2/3 (114/1034=11.0%
versus 243/1287=18.9%; P,0.001). Methylation of 1, 2, 3, 4 and
$5 CpGs was detected in 62, 21, 15, 17, and 23 samples, respectively.
The likelihood of being diagnosed as CIN2/3 increased significantly
with decreasing numbers of meCpGs (Pfor trend=0.003).
The frequencies of methylation at individual CpG sites ranged
from 6.4% at position 7883 to 19.1% at position 43 among women
with CIN2/3 and from 11.1% at position 7695 to 26.5% at
position 31 among those without CIN2/3 (Figure 2). It is visually
apparent that women with CIN2/3 compared to those without
had lower proportions of meCpGs across all sites except for
position 7695. Despite an overall higher frequency of methylation
in the promoter than in the enhancer (193/1055=18.3% versus
128/1055=12.1%, p,0.001), the pattern of lower frequencies of
meCpGs among women with CIN2/3 compared to those without
remained the same for both regions (37/470=7.9% versus 91/
585=15.6%, p,0.001 for the enhancer; 63/470=13.4% versus
130/585=22.2%, p,0.001 for the promoter).
Risk of CIN2/3 associated with degree of HPV16 DNA
methylation
Table 2 shows the association of CIN2/3 with degree of HPV16
DNA methylation. The presence of $4 meCpGs in the 39 end of
the long control region was found in 8 (8.5%) of 94 women with
CIN2/3 and 32 (27.4%) of 117 women without. After adjusting for
HPV16 variants, number of HPV16 positive visits, current
smoking status and lifetime number of male sex partners, the risk
of CIN2/3 was significantly inversely associated with $4 meCpGs
(OR adjusted=0.31; 95% CI, 0.12–0.79). Additional adjustment for
age at screening or race did not alter the risk estimates appreciably
(data not shown). The inverse association remained statistically
significant or marginally statistically significant when the methyl-
ation status was based on CpGs in the enhancer and promoter,
separately. As shown in Table 2, the 95% CIs estimated by a
bootstrap with 10,000 repetitions of re-sampling 5 clones per
sample were slightly narrow relative to the corresponding ones
derived from the actual data. The patterns of the associations
remained similar when 10 clones per sample were drawn for the
bootstrap computation (data not shown).
Thirty-three women (9 with CIN2/3 and 24 without) had
HPV16 DNA detected at the screening visit alone. An exclusion of
these women from the analysis did not appreciably alter the
association of CIN2/3 with $4 meCpGs in the 39 end of the long
control region (OR adjusted=0.27; 95% CI, 0.09–0.82). Co-infection
with other oncogenic HPV types was detected in 68 (32.2%) of 211
women. The association of CIN2/3 with $4 meCpGs remained
similar when the analysis was restricted to women without co-
infection of other oncogenic types (OR adjusted=0.15; 95% CI,
0.04–0.53). Given the significant association of $4 meCpGs in the
39 end of the long control region with risk of CIN2/3, we further
examined its impact on the lesion severity.
HPV16 DNA methylation-related lesion severity
Of 211 women who provided one or more tissue samples for
diagnosis, CIN1, CIN2, or CIN3 was histologically confirmed in 30,
32, and 62 women, respectively. As shown in Figure 3, the proportions
of $4m e C p G si nt h e3 9 end of the long control region decreased
a p p r e c i a b l yw i t ha ni n c r e a s ei nl e s i o ns e v e r i t y( Pfor trend=0.001).
When CIN3 was used as the endpoint, the adjusted OR for the
association with $4 meCpGs was 0.22 (95% CI, 0.07–0.74).
Data from the univariate analyses suggested a difference in
CIN2/3 prevalence between current and noncurrent smokers. A
question raised is whether the methylation-associated risk was
modified by smoking habit.
HPV16 DNA methylation-associated risk of CIN2/3,
stratified by smoking status
The presence of $4 meCpGs in the 39 end of the long control
region was detected in 14 (13.6%) of 103 current smokers and 26
(24.1%) of 108 noncurrent smokers (p=0.05). Although the
HPV16 DNA Methylation and Risk of CIN2/3
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Characteristic
a Without CIN2/3 With CIN2/3
no. (%) no. (%) P
Age at screening, years 0.56
18–20 33 (28.2) 19 (20.2)
21–25 54 (46.2) 47 (50.0)
26–30 20 (17.1) 17 (18.1)
$31 10 (8.5) 11 (11.7)
Race
b 0.65
Caucasian 84 (73.7) 64 (68.1)
African-American 11 (9.6) 10 (10.6)
Others 19 (16.7) 20 (21.3)
Lifetime no. of male sex partners
c 0.12
0–4 33 (28.2) 15 (16.1)
5–9 39 (33.3) 36 (38.7)
$10 45 (38.5) 42 (45.2)
Having new sex partners since screening 0.67
No 105 (89.7) 86 (91.5)
Yes 12 (10.3) 8 (8.5)
Age at the first sexual intercourse, years
d 0.66
9–15, 47 (41.2) 39 (44.3)
$16 67 (58.8) 49 (55.7)
Current hormonal contraceptive use 0.25
No 68 (58.1) 62 (66.0)
Yes 49 (41.9) 32 (34.0)
Current smoking 0.05
No 67 (57.3) 41 (43.6)
Yes 50 (42.7) 53 (56.4)
Coinfection with other oncogenic HPV types 0.61
No 81 (69.2) 62 (66.0)
Yes 36 (30.8) 32 (34.0)
HPV16 infections detected at 0.01
Screening visit alone 24 (20.5) 9 (9.6)
Colposcopy visit alone 24 (20.5) 10 (10.6)
Both 69 (59.0) 75 (79.8)
HPV16 variant lineage
e 0.03
European variants 103 (90.4) 75 (79.8)
Non-European variants 11 (9.6) 19 (20.2)
Cytologic findings at screening
f ,0.001
Within normal limits 65 (56.5) 19 (20.2)
ASC-US 23 (20.0) 15 (16.0)
LSIL 16 (13.9) 14 (14.9)
HSIL 11 (9.6) 46 (48.9)
aCharacteristics were based on information at the screening visit with the exceptions of having new sex partners since screening (collected at the colposcopy visit) and
co-infection with other oncogenic HPV types, which was based on information at the visit from which the sample was assayed for methylation.
bThree women who did not provide information on race were excluded. The category of ‘‘Others’’ includes American Indian/Alaskan Native, Asian/Pacific Islander
women and others.
cOne woman who did not provide information on lifetime number of male sex partners was excluded.
dNine women who did not provide information of age at the first sexual intercourse were excluded.
eThree women whose sample was inadequate for variant characterization were excluded.
fTwo women whose sample was inadequate for cytologic evaluation were excluded.
doi:10.1371/journal.pone.0023897.t001
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current smokers (Table 3, OR=0.12; 95% CI, 0.03–0.59) than in
noncurrent smokers (OR=0.40, 95% CI, 0.15–1.11), the test for
interaction between smoking and methylation did not reach a
statistically significant level (P=0.21).
The risk association between CIN2/3 and $4 meCpGs in the
39 end of the long control region did not differ meaningfully by age
at screening, race, HPV16 variants, or number of HPV16 positive
visits (data not shown).
Discussion
In this study, we found that most CpGs in the 39 end of the long
control region were unmethylated; the likelihood of being
diagnosed as CIN2/3 was significantly inversely associated with
$4 meCpGs in this region. There was a trend showing an increase
in lesion severity with a decrease in the proportion of $4 meCpGs.
The inverse association was not explained by factors known to be
relevant to the development of a cervical lesion including HPV16
variants, number of HPV16 positive visits, smoking status, and
lifetime number of male sex partners nor by age and race. As
shown by the analysis restricted to women without co-infection of
other oncogenic HPV types, the association was also unlikely to
result from effects of other HPV types. We are aware that
methylation status might be unrelated to CIN2/3, if the infection
became undetectable at the colposcopy visit. The association
remained similar when the analysis was restricted to women who
had HPV16 DNA detected at the colposcopy visit.
It should be pointed out that numbers of meCpGs defined in
this study represented the methylation status of the infection rather
than individual viral copies. While this analytic strategy minimizes
ascertainment biases possibly introduced by counting exposures
Figure 1. Patterns of CpG methylation in the 39 end of the long control region of HPV16. Grey and black rectangles represent
unmethylated and methylated CpGs, respectively. The numbers below the nucleotide position indicate a cytosine’s position of each CpG
dinucleotides.
doi:10.1371/journal.pone.0023897.g001
Figure 2. Proportions of the methylated cytosine at individual CpG dinucleotides between women with and without CIN2/3. Grey
and white bars represent women with and without a diagnosis of CIN2/3, respectively. The numbers above the nucleotide position indicate a
cytosine’s position of each CpG dinucleotides in the 39 end of the long control region of HPV16 genome.
doi:10.1371/journal.pone.0023897.g002
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analyzed.
No. of methylated Without CIN2/3 With CIN2/3 Crude OR Adjusted OR 95% CI by
CpGs within




0 39 (33.3) 34 (36.2) 1.00 1.00
1 27 (23.1) 35 (37.2) 1.49 (0.75–2.94) 1.49 (0.71–3.13) 0.98–1.89
2–3 19 (16.2) 17 (18.1) 1.03 (0.46–2.28) 0.89 (0.38–2.08) 0.63–1.23
$4 32 (27.4) 8 (8.5) 0.29 (0.12–0.71) 0.31 (0.12–0.79) 0.14–0.35
Enhancer region
0 66 (56.4) 68 (72.3) 1.00 1.00
1 27 (23.1) 17 (18.1) 0.61 (0.31–1.22) 0.76 (0.36–1.59) 0.44–0.83
$2 24 (20.5) 9 (9.6) 0.36 (0.16–0.84) 0.39 (0.16–0.94) 0.22–0.44
Replication origin
0 95 (81.2) 80 (85.1) 1.0 1.0
1 22 (18.8) 14 (14.9) 0.76 (0.36–1.57) 0.70 (0.32–1.52) 0.55–1.01
Promoter region
0 58 (49.6) 56 (59.6) 1.00 1.00
1 25 (21.4) 21 (22.3) 0.87 (0.44–1.73) 0.70 (0.33–1.48) 0.63–1.19
$2 34 (29.1) 17 (18.1) 0.52 (0.26–1.03) 0.53 (0.26–1.11) 0.38–0.60
aOf 11 CpGs in the 39 end of the long control region, 5 were within the enhancer region and 5 within the promoter region.
bAdjusted for HPV16 variants, number of HPV16 positive visits, current smoking status, and lifetime number of male sex partners.
cUpper and lower bounds of 95% CI estimated by bootstrapping 5 clones per sample for 10,000 times.
doi:10.1371/journal.pone.0023897.t002
Figure 3. Proportions of $4meCpGs in the 39 end of the long control region, stratified by cervical lesion severity.
doi:10.1371/journal.pone.0023897.g003
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clones per sample. Previous studies usually examined 5 clones per
sample and treated each clone as a single data-point [18,22,30,31].
Although an analysis of 10 clones per sample was reported, it
included only 16 samples [32]. We acknowledge that because of a
heterogeneous methylation status, more meCpGs would have
been identified if more clones had been sequenced. However, this
influence is likely to be non-differential because the present study
assayed the same number of clones for virtually all samples. As
suggested by the bootstrap analysis, sequencing more clones might
improve a precision of the estimate by narrowing the confidence
interval but not appreciably change the estimate of the risk
association.
The present report is not the first to compare HPV16 DNA
methylation status between women with and without a cervical
lesion; but one of the first, if not the first study, to comprehensively
address the impact of degree of CpG methylation on the
development of CIN2/3 in a well defined screening population.
In an earlier study of HPV16 methylation using methylation-
specific restriction endonuclease digestion and direct sequencing of
PCR products [17], CpG methylation in the long control region
was found to be common in samples without abnormal cells, less
common in samples with cells showing precancerous changes, and
rare in samples with cancerous cells. In another study of HPV16
methylation (performed by subcloning and sequencing) [18], the
frequency of methylation was found to be highest in specimens
from cancer patients and lowest in women with cervical neoplasia.
An association between lower levels of HPV16 methylation
(hypomethylation) and cervical neoplasia has been reported by
some studies [19,20] but not others [21,22]. The discrepancy of
these results could be due to differences in study populations and
approaches for methylation testing or a lack of sufficient statistical
power.
The present study not only confirms the inverse association
previously reported by some studies, but also extends previous
findings by showing that the impact of methylation on risk of
CIN2/3 depends on the number of detectable meCpGs in the 39
end of the long control region. As compared to infections without
detectable meCpG, risk of CIN2/3 was substantial for those with
$4 meCpGs in the 39 end of the long control region but not for
those with a single meCpG. This methylation degree-related risk
of CIN2/3 may in part explain discrepancies in previous reports
because these studies usually dichotomized the status as methyl-
ated and unmethylated for risk assessment.
The underlying mechanism for the methylation-associated risk
of CIN2/3 is presently unclear but it may result from a
methylation-related alteration in the life-cycle of the virus. As
shown in a schematic drawing by Ding et al [22], CpGs in the 39
end of the long control region are at positions close to or within the
binding sites for E2 proteins and various transcriptional factors.
For example, positions 7535, 7554 and 7683 are close to AP1 and
NF1 sites; position 7862 is close to CDP and AP1 sites and part of
an E2 site; position 31 is within the SP1 site; and positions 37, 43,
52 and 58 are within the first two E2 binding sites next to the P97
promoter. Evidence from in vitro studies suggests that methylation
of the HPV16 or HPV18 genome leads to a substantial repression
of transcriptional activities by either directly or indirectly blocking
the binding of the transcription factors [8,33] or the E2 protein
[9,10] to elements in the long control region. Recent studies
further showed a correlation between an increase in CpG
methylation and decrease in expression of the E6 gene [20,34].
Given the etiologic role of the oncogene’s products, escape from
this repression possibly by demethylation is likely to be a
prerequisite for neoplastic progression.
The number of cases of cervical cancer in this study was too
small (n=2) to form a valid group for risk assessment. As noted,
the highest frequency of HPV16 DNA methylation among cervical
cancer patients was reported in most previous studies [18,22,35].
This does not conflict with our findings of hypomethylation-
associated risk of CIN2/3. It is possible that the HPV genome in
early stages of infection has to become demethylated in order to
permit active viral transcription to initiate the transforming
process. As carcinogenesis progresses, however, viral DNAs are
frequently integrated into the host genome [36]. The heavy
methylation seen among cancer patients might result from a host
defense mechanism which senses the integrated viral genome as
foreign [37,38] and targets it for epigenetic modification. While
the methylation resumes because of the integration, particularly
for those tandem repeats, some HPV genomes remain unmethy-
lated in cancer cells to maintain the transformed phenotype [39].
Consistent with findings reported by others [40,41,42,43,
44,45,46], CIN2/3 occurred more frequently among current, as
compared to noncurrent, smokers. Interestingly, the inverse as-
sociation between risk of CIN2/3 and HPV16 DNA methylation
appeared more substantial among women who self-reported as
current smokers than among those who did not, although the test
for interaction was not statistically significant. As shown in an in
vitro study [47], exposure of cervical cells to Benzo[a]pyrene, a
major carcinogen in cigarette smoke, stimulated higher levels of
virion synthesis in HPV-infected cell lines. The smoke-associated
increase in viral load was also observed in a population of HPV16-
positive women [48]. Given an observation of lower proportion of
infections with $4 meCpGs among current, as compared to
noncurrent, smokers, we hypothesize that both cigarette smoke
and HPV16 DNA methylation may play a role either indepen-
dently or jointly in increasing CIN2/3 risk, perhaps by enhancing
Table 3. Odds ratios and 95% confidence intervals for the association of CIN2/3 with $4meCpGs in the 39 end of the long control
region, stratified by current smoking status.
Current smoking $4meCpGs in the Without CIN2/3 With CIN2/3
long control region no. (%) no. (%) OR (95% CI)
a
Yes No 38 (42.7) 51 (57.3) 1.00
Yes Yes 12 (85.7) 2 (14.3) 0.12 (0.03–0.59)
No No 47 (57.3) 35 (42.7) 1.00
No Yes 20 (76.9) 6 (23.1) 0.40 (0.15–1.11)
aThe unadjusted OR was provided because of a small number of current smokers with $4meCpGs in the 39 end of the long control region, particularly for those with a
diagnosis of CIN2/3.
doi:10.1371/journal.pone.0023897.t003
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cigarette smoke and HPV16 DNA methylation on neoplastic
progression warrants further investigation.
Several limitations of the study should be addressed. Despite the
fact that this study included the largest number of infections to
date, the number with $4 meCpGs among current smokers was
small, particularly for those with a diagnosis of CIN2/3. Thus, the
finding of a joint effect of smoking and methylation should be
interpreted with caution. Secondly, cervical swab collects a mixed
population of cells. Thus, the methylation detected in such a
sample reflects the average of the HPV16 genomes from various
cells. This as compared to use of microdissected uniform cells may
attenuate a difference in methylation between women with and
without CIN2/3, thereby leading to an underestimate of the risk
association. Lastly, our study subjects were generally young. It is
unclear whether the patterns of HPV16 methylation and their
associations with risk of CIN2/3 would be the same for older
women. However, due to a high proportion of young women
attending Planned Parenthood Clinics both locally and nationally
for Pap screening, our results are generalizable to a large segment
of women between 18 and 50 years of age.
In summary, our data indicate that risk of CIN2/3 is inversely
associated with degree of CpG methylation in the 39 end of the
long control region of the HPV16 genome. The association might
be mediated through a methylation-related alteration in the
biologic behavior of the virus.
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